Answers are grounded in this paper and cite their sources.
A summary of the reports is presented, which are included in the database of the World Health Organization's international drug monitoring program as of March 23, 2022 on the use of rivaroxaban, recommended for the use of the prevention of thrombotic complications and the most often combined drug found in clinical practice. Cases of drug interaction were analyzed and safety analysis of combination therapy was carried out. This material is presented for doctors, researchers, health regulators.
No takes yet. Share an insight, caveat, or question.
Andrey Kondrakhin (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: